Avalyn Pharma
Targeted therapies for rare lung diseases
Targeted therapies for rare lung diseases
Avalyn Pharma Inc. is a **clinical-stage biopharmaceutical** company focused on developing inhaled therapies to treat rare respiratory diseases, emphasizing idiopathic pulmonary fibrosis and other interstitial lung diseases. **Founded in 2011** and headquartered in the **United States**, Avalyn is committed to developing **targeted therapies** for these uncommon ailments. The company's lead candidate, **AP01**, is a Phase 2b-ready inhaled formulation of pirfenidone designed for the treatment of pulmonary fibrosis. Recently, the company secured a significant **$175.00M Series C investment** on **27 September 2023**. The investment was led by a consortium of notable investors, including **Novo Holdings, F-Prime Capital, Norwest Venture Partners, Pivotal bioVenture Partners, RiverVest, Perceptive Advisors, Rock Springs Capital, SR One, Vida Ventures, and Surveyor Capital.** This substantial investment affirms confidence in the company's vision and potential to revolutionize the treatment of rare lung diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $175.00M | 10 |
|
27 Sep 2023 |
| Series B | $35.50M | - | 27 Apr 2020 | |
| Series A | $62.00M | - | 01 Jan 2017 |
No recent news or press coverage available for Avalyn Pharma.
We care about your data, and we'd love to use cookies make your experience better.
